Results 131 to 140 of about 115,882 (349)

Switching Enzyme Replacement Therapy for Late‐Onset Pompe Disease From Alglucosidase Alfa to Cipaglucosidase Alfa Plus Miglustat: Post Hoc Effect Size Analysis of PROPEL

Muscle &Nerve, EarlyView.
A total of 95 ERT‐experienced adults with LOPD were randomized to switch to cipaglucosidase alfa + miglustat or remain on alglucosidase alfa treatment. After 52 weeks, patients remaining on alglucosidase alfa showed worsening or stability for most outcomes, whereas patients who switched to cipaglucosidase alfa + miglustat generally showed stability or ...
Hani Kushlaf, Jordi Díaz‐Manera, Drago Bratkovic, Barry J. Byrne, Kristl G. Claeys, Paula R. Clemens, Mazen M. Dimachkie, Priya S. Kishnani, Pascal Laforêt, Mark Roberts, Benedikt Schoser, Antonio Toscano, Jeff Castelli, Fred Holdbrook, Sheela Sitaraman Das, Mitchell Goldman, Tahseen Mozaffar, on behalf of the PROPEL Study Group   +17 more
wiley   +1 more source

Characteristic and Correlation Between TIME and Complication After Destructive Eye Procedure Patient at Plastic and Reconstruction Division Sanglah Hospital\u27s Eye Clinic Bali-Indonesia [PDF]

, 2012
Destructive eye procedure can be carried out by enucleation, evisceration and excenteration. Some efforts have been developed to reduce the complications, but it still occur within several years after the operation.
Sukartini, D. (D), Triharpini, N. (N), Yuliawati, P. (P)   +2 more
core   +2 more sources

Design of and Early Insights From a Generalized Myasthenia Gravis Patient Engagement Research Council

Health Science Reports
Background and Aims An exploratory focus group study was conducted to better understand the needs of patients living with generalized myasthenia gravis (gMG).
Gabrielle Geonnotti, Jacqueline Pesa, Wesley Peters, Melina Taylor, Zia Choudhry, Oluyemisi Falope, Marquetta Price, Lucy Baxter, Bruce West, Lisa Shea   +9 more
doaj   +1 more source

Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis

Neurology and Therapy, 2023
This article provides a summary of a previously published paper: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. The paper reported the results of the CHAMPION-MG trial which investigated the drug ravulizumab in the rare ...
Tuan Vu, Andreas Meisel, Renato Mantegazza, Djillali Annane, Masahisa Katsuno, Rasha Aguzzi, Ahmed Enayetallah, Kathleen N. Beasley, Nishi Rampal, James F. Howard   +9 more
doaj   +1 more source

Transcranial direct current stimulation to remediate myasthenia gravis symptoms [PDF]

arXiv, 2019
Our findings indicated that brain stimulation exerted no effect on the patients cognitive functions. The study outcome suggest that tDCS over primary motor cortex may be considered as a potential nonpharmochological treatment add-on in MG. Larger-sized studies need to evaluate the significance of this approach is real-life practice.
arxiv  

Octonionic Gravi-electromagnetism and Dark Matter [PDF]

, 2014
An attempt has been made to analyse the the role of octonions in various unified field theories associated with dyons and the dark matter. Starting with the split octonion al- gebra and its properties, we have discussed the octonionic unified gauge formulation for SU(2) ?X U(1) electroweak theory and SU(3) X? SU(2) ?X U(1) grand unified theory.
arxiv   +1 more source

Mycophenolate Facilitates Improvement in Outcome Measures in Treatment Resistant Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Muscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a potentially disabling autoimmune neuropathy. Approximately 20% of patients are refractory to first‐line treatments necessitating second‐line options with limited evidence and potential adverse effects.
Shamim Miah, Nicole Japzon, Amar Elsaddig, Shiwen Koay, Laura Compton, Michael P. Lunn, Aisling S. Carr   +6 more
wiley   +1 more source

International consensus guidance for management of myasthenia gravis

Neurology, 2016
Objective: To develop formal consensus-based guidance for the management of myasthenia gravis (MG). Methods: In October 2013, the Myasthenia Gravis Foundation of America appointed a Task Force to develop treatment guidance for MG, and a panel of 15 ...
D. Sanders, G. Wolfe, M. Benatar, A. Evoli, N. Gilhus, I. Illa, N. Kuntz, J. Massey, A. Melms, H. Murai, M. Nicolle, Jacqueline A Palace, D. Richman, J. Verschuuren, P. Narayanaswami   +14 more
semanticscholar   +1 more source

A Review of Psychiatric Comorbidity in Myasthenia Gravis

Cureus, 2020
This study aimed to review studies focused on the affective comorbidities associated with myasthenia gravis and to determine the extent to which neuromuscular treatment modalities address non-somatic aspects of autoimmune myasthenia gravis.
Christina Law, C. Flaherty, S. Bandyopadhyay   +2 more
semanticscholar   +1 more source

Measuring Adverse Event Burden in Myasthenia Gravis: Retrospective Validation of the Adverse Event Unit With Randomized Trial of Thymectomy in Myasthenia Gravis Data

Muscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims The Adverse Event Unit (AEU) is a patient and physician weighted unit that quantifies and compares adverse event (AE) burden among any neurologic treatments. A recent study demonstrated feasibility and preliminary validity of the AEU in myasthenia gravis (MG).
Michael K. Hehir, Inmaculada B. Aban, Henry J. Kaminski   +2 more
wiley   +1 more source